These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8889656)

  • 1. Application of the lateral/facial protection model to a new molecule, iobitridol.
    Violon D
    Invest Radiol; 1996 Oct; 31(10):668-70. PubMed ID: 8889656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the factors influencing the osmolality of eight monomeric nonionic iodinated contrast medium molecules.
    Violon D
    Invest Radiol; 1997 Nov; 32(11):684-9. PubMed ID: 9387056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of the hydrophilic sphere of iobitridol, a new nonionic iodinated contrast agent.
    Meyer D; Petta M; Fouchet MH; Vadel M; Schaefer M; Dugast-Zrihen M; Guillemot M
    Acta Radiol Suppl; 1996; 400():8-16. PubMed ID: 8619359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of some geometric parameters derived from molecular models of monomer nonionic contrast medium molecules with their octanol/water partition coefficient.
    Violon D
    Invest Radiol; 1996 Sep; 31(9):569-76. PubMed ID: 8877494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of the hydrophilic sphere of iobitridol.
    Carrupt PA; Testa B
    Br J Radiol; 2003 Feb; 76(902):147; author reply 147-8. PubMed ID: 12642287
    [No Abstract]   [Full Text] [Related]  

  • 6. Stabilization of the hydrophilic sphere of non-ionic monomers: are all protected in a similar way?
    Violon D
    Br J Radiol; 2001 Dec; 74(888):1097-102. PubMed ID: 11777766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the complex between the contrast agent Iobitridol (Xenetix) and Elastase (PPE): a model for hydrophobic site protection in drug-protein interactions.
    Prangé T; Neuman A; Corot C; Meyer D
    Pharm Res; 1997 Dec; 14(12):1713-7. PubMed ID: 9453058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilization of the hydrophilic sphere of iobitridol, an iodinated contrast agent, as revealed by experimental and computational investigations.
    Meyer D; Fouchet MH; Petta M; Carrupt PA; Gaillard P; Testa B
    Pharm Res; 1995 Nov; 12(11):1583-91. PubMed ID: 8592654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative toxic effects of iobitridol and iohexol on the kidney.
    Wasaki M; Kawamura H; Sugimoto J; Shimada M; Satoh Y; Tanaka E; Gemba M
    Invest Radiol; 1998 Jul; 33(7):393-400. PubMed ID: 9659591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplacental passage and milk excretion of iobitridol.
    Bourrinet P; Dencausse A; Havard P; Violas X; Bonnemain B
    Invest Radiol; 1995 Mar; 30(3):156-8. PubMed ID: 7797413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computation of the solvent-accessible surface area of monomer nonionic contrast media. Consequences for used probe radius in the study of hydrophilic characteristics.
    Violon D
    Invest Radiol; 1997 Feb; 32(2):126-30. PubMed ID: 9039586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of biodistribution and changes in density following administration of iobitridol in rabbits. A comparative study vs iohexol.
    Rouleau P; Alison D; Bertrand P; Benderbous S; Havard P; Chambon C
    Acta Radiol Suppl; 1996; 400():49-55. PubMed ID: 8619352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of the new iodinated nonionic low-osmolality contrast medium Iobitridol (Xenetix) in coronary and ventricular angiography.
    Lefevre T; Funck F; Aliot E; Ethevenot B
    Acta Radiol Suppl; 1996; 400():75-80. PubMed ID: 8619358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of a new monomeric nonionic radiographic contrast medium (iobitridol-350 versus NaCl) on cutaneous microcirculation: single-center, prospective, randomized, double-blind phase IV study in parallel group design.
    Bach R; Gerk U; Mrowietz C; Jung F
    Microvasc Res; 2000 Nov; 60(3):193-200. PubMed ID: 11078635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iobitridol, a new nonionic low-osmolality contrast agent, and iohexol. Impact on renal histology in the rat.
    Beaufils H; Idée JM; Berthommier C; Balut C; Bourbouze R; Nimier K; Chicandre-Jouanneau C; Bonnemain B
    Invest Radiol; 1995 Jan; 30(1):33-9. PubMed ID: 7759214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic profile of iobitridol, a nonionic iodinated contrast medium.
    Idee JM; Bault C; Beaufils H; Berthommier C; Cambar J; Corot C; Doucet D; Hartl C; Jaudon MC; Jacquiaud C; Lakhdar B; Potier M; santus R; Torcherie S; Vaudon E; Bonnemain B
    Acta Radiol Suppl; 1996; 400():35-48. PubMed ID: 8619351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicologic profile of iobitridol, a new nonionic low-osmolality contrast medium.
    Donandieu AM; Idee JM; Doucet D; Legros A; Penati S; Nain-Dit-Ducret M; Marmion F; Bonnemain B
    Acta Radiol Suppl; 1996; 400():17-24. PubMed ID: 8619348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical tolerance and diagnostic efficacy of iobitridol in contrast-enhanced CT in children.
    Smets A; Shaw D
    Acta Radiol Suppl; 1996; 400():65-7. PubMed ID: 8619355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Iodinated Radiographic Contrast Media on Multidrug-resistant K562/Dox Cells: Mitochondria Impairment and P-glycoprotein Inhibition.
    Supawat B; Udomtanakunchai C; Kothan S; Tungjai M
    Cell Biochem Biophys; 2019 Jun; 77(2):157-163. PubMed ID: 30924055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of iobitridol versus iohexol for contrast-enhanced CT of the head.
    Drouillard J; Froment JC; Frija G; Caille JM; Gandon Y; Clarisse J; Gaston A
    Acta Radiol Suppl; 1996; 400():56-61. PubMed ID: 8619353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.